Jefferies & Co downgrades Gilead Sciences (GILD) to Hold
More News related to GILD
- Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008
- Notable Analyst Rating Changes 10/3: COST, CS, CSX, URBN Upgraded; CMI, WAG, SGP, SCG Downgraded
- Merrill Lynch Resumes Coverage on Gilead Sciences (GILD)
- Citi Maintains a 'Buy' on Gilead Sciences (GILD), Saying Stock is Oversold
- David Moenning's Daily State of the Markets: 9/24
More News related to Downgrades
- Canaccord Adams Downgrades Freeport-McMoRan (FCX) to Sell, Slashes Price Target
- Jefferies Downgrades Advanced Medical Optics (EYE) to Underperform
- Susquehanna Downgrades Isle of Capri Casinos (ISLE) to Neutral
- Susquehanna Downgrades Boyd Gaming Corporation (BYD) to Neutral
- Susquehanna Downgrades MGM MIRAGE (MGM) to Neutral
Jefferies & Co downgrades Gilead Sciences (Nasdaq: GILD) from Buy to Hold. Price target $56.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
DowngradesStocks Mentioned
-2.57Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
